Oct 09, 2024 8:00am EDT bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
Sep 18, 2024 8:00am EDT Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
Aug 23, 2024 5:15pm EDT bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
Aug 14, 2024 9:25am EDT bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales
Aug 05, 2024 1:17pm EDT bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
Aug 02, 2024 9:25am EDT bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
Jul 09, 2024 8:00am EDT bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung
Jun 12, 2024 8:00am EDT bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
May 15, 2024 9:15am EDT bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
